PR Newswire | Oct 26, 2021 07:31AM EDT

10/26 06:30 CDT

Enveric Biosciences to Participate in Wonderland: Miami Conference NAPLES, Fla., Oct. 26, 2021

NAPLES, Fla., Oct. 26, 2021 /PRNewswire/ -- Enveric Biosciences(NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in the upcoming Wonderland: Miami conference:

* Microdose Presents Wonderland: Miami to be held in-person in Miami, Florida from November 8-9, 2021. Dr. Tucker will be speaking on the Next-Generation Psychedelics panel live on Monday, November 8th at 3:10 p.m. ET. Register to attend here.

For more information about the conferences, or to schedule a one-on-one meeting with Enveric's management team, please contact your Microdose representatives directly, or send an email to KCSA Strategic Communications at envericbio@kcsa.com.

About Enveric BiosciencesEnveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com.

Investor ContactsValter Pinto / Allison Soss KCSA Strategic Communications 212.896.1254 / 212.896.1267 valter@kcsa.com / asoss@kcsa.com

Media ContactsRaquel Cona / Joe McIntyreKCSA Strategic Communications 212.896.1204 / 856.381.8996 rcona@kcsa.com / jmcintyre@kcsa.com

View original content: https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-wonderland-miami-conference-301408112.html

SOURCE Enveric Biosciences